Genentech
VABYSMO
Manufacturer:
Genentech
Name:
VABYSMO
HCPCS Code Descriptor:
Injection, faricimab-svoa, 0.1 mg
Category:
J Code
HCPCS:
J2777
NDC(s):
50242-0096-01
Primary Type:
Opthalmic
Generic Status:
Single-Source
Route of Administration:
Intraocular
About:
VABYSMO is an Opthalmic drug manufactured by Genentech and administered via the Intraocular route of administration. The J Code: J2777 is aligned to the drug VABYSMO.
Vabysmo belongs to the class of drugs known as anti-angiogenic ophthalmic agents. Vabysmo is used to treat certain eye disorders and works by stopping two disease pathways in the eye that are thought to cause instability. Vabysmo is a branded drug manufactured by Genentech USA. From July 2022 to September 2022, Vabysmo was aligned to the C Code: C9097. Beginning in October 2022, Vabysmo has been aligned to the J Code: J2777. Patient assistance programs for this medication can be found through Genentech.
Access Pricing and More By Registering
HCPCS Added Date:
10/1/22
HCPCS Effective Date:
10/1/22
HCPCS Short Description:
Inj, faricimab-svoa, 0.1mg
Billing and Coding Guide:
https://www.genentech-access.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf
Patient Assistance:
https://www.gene.com/patients/patient-foundation/apply-for-help#patients
